← Leaderboards
Anita C Gilliam
Case Western Reserve University
$2,181,316
Attributed
$2,181,316
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $309.9K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$2,181,316 · 6
By mechanism
R01$1,226,098 · 1
K08$366,120 · 1
R21$344,250 · 1
R03$153,000 · 1
P30$91,848 · 2
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Kevin D Cooper$16,666,288
- Richard E Zigmond$14,345,843
- Aaron Weinberg$13,644,444
Others in their field
Top investigators on “Monocyte”
- Steven Kyle Grinspoon · Massachusetts General Hospital$29,810,751
- Pamela Susan Douglas · Duke University$25,187,001
- Gyongyi Szabo · Univ Of Massachusetts Med Sch Worcester$24,671,476
- Joan Weinberger Berman · Yeshiva University$24,336,702
- Robert L Modlin · University Of California Los Angeles$24,201,619
- Yuri Persidsky · Temple Univ Of The Commonwealth$23,010,146
Research focus
MonocyteLaboratory MouseGraft Versus Host DiseaseFlow CytometryTransforming Growth FactorsSclerodermaGene TherapyInhibitor /AntagonistMacrophageDisease /Disorder ModelPathologic ProcessRnase Protection AssayBone Marrow TransplantationFibroblastsSkin DisorderIn Situ HybridizationFibrosisChemokineCollagenImmunotherapyPolymerase Chain ReactionTissue /Cell CultureGenetically Modified AnimalsAntibody
Grant awards (16)
Immune mechanisms that lead to irreversible scleroderma$297,034
R01 · FY2007 · AR · contact PI
Immune mechanisms that lead to irreversible scleroderma.$305,905
R01 · FY2006 · AR · contact PI
Immune mechanisms that lead to irreversible scleroderma.$309,891
R01 · FY2005 · AR
Immune mechanisms that lead to irreversible scleroderma$313,268
R01 · FY2004 · AR
Chemokine antagonists in a murine model for scleroderma$114,750
R21 · FY2003 · AR
INHIBITION OF MONOCYTE TGFB1-INDUCED SKIN FIBROSIS$122,040
K08 · FY2002 · AR
Chemokine antagonists in a murine model for scleroderma$114,750
R21 · FY2002 · AR
CORE--CELLULAR AND MOLECULAR MORPHOLOGY$45,924
P30 · FY2002 · AR
Pilot--Monocyte directed gene transfer of TGF beta-1$0
P30 · FY2002 · AR
INHIBITION OF MONOCYTE TGFB1-INDUCED SKIN FIBROSIS$122,040
K08 · FY2001 · AR
Chemokine antagonists in a murine model for scleroderma$114,750
R21 · FY2001 · AR
LATENCY-ASSOCIATED PEPTIDE AS AN INHIBITOR OF TGFB-INDUC$76,500
R03 · FY2001 · AR
CORE--CELLULAR AND MOLECULAR MORPHOLOGY$45,924
P30 · FY2001 · AR
Pilot--Monocyte directed gene transfer of TGF beta-1$0
P30 · FY2001 · AR
INHIBITION OF MONOCYTE TGFB1-INDUCED SKIN FIBROSIS$122,040
K08 · FY2000 · AR
LATENCY-ASSOCIATED PEPTIDE AS AN INHIBITOR OF TGFB-INDUC$76,500
R03 · FY2000 · AR